Editor's note

Originally published March 2022. This article captures the pipeline landscape at a pivotal moment in the mRNA technology adoption curve. For the current updated pipeline review across all major developers and platforms, see VAMV084 - Vaccines/mRNA Strategic Pipeline Review (2025, sample available).

The Scale of the Shift

In Q1 2022, VacZine Analytics conducted a systematic review of the R&D pipelines of seven major vaccine developers: GSK, Sanofi, Pfizer/BioNTech, Merck, Johnson & Johnson, Moderna, and AstraZeneca/Oxford. Across these companies, 59 vaccine programmes were identified spanning 27 distinct pathogens or therapeutic indications.

The most striking finding was the proportion of nucleic acid-based programmes. Prior to 2020, nucleic acid (mRNA and DNA) approaches represented fewer than 5% of active industrial vaccine programmes. By Q1 2022, that share had risen to approximately one third of the combined pipeline - a shift extending beyond COVID-19 programmes into oncology, respiratory, and sexually transmitted infections.

Pipeline count · Q1 2022
59

Verified active vaccine programmes across 7 major developers, spanning 27 pathogens and indications. Approximately one third are nucleic acid-based. Source: VacZine Analytics original pipeline audit.

Company by Company

GSK leads in absolute pipeline breadth with 16 programmes. Moderna follows with 12 - impressive for a company with no licensed product before December 2021. RSV remains the most-worked pathogen with 9 separate programmes across multiple companies and platforms. Sanofi, GSK, and Pfizer are all building nucleic acid capability alongside established platforms. Moderna's HIV programme (mRNA-1574) exemplifies the broad application thesis - applying mRNA to a pathogen area where traditional approaches have repeatedly failed. Sanofi's mRNA programmes span influenza (SP0273), COVID-19 (SP0253), and RSV in older adults.

"Fewer than 5% of industrial vaccine trials were nucleic acid-based in 2019. By Q1 2022, that figure had risen to approximately one third - a structural shift that will define the next decade of vaccine development."

What This Means for the Market

The mRNA platform's dominance in COVID-19 response demonstrated manufacturing scalability and regulatory adaptability that was previously theoretical. The central question for industry post-2022: do these platform advantages translate to non-pandemic settings where development timelines, pricing, and cold chain logistics are determined by normal commercial pressures? VacZine Analytics tracks programme status and clinical outcomes in VAMV084 - Vaccines/mRNA Strategic Pipeline Review.